Jul 2, 2010 by Brian Orelli, PhDArena Got TakenA billion-dollar market and that's all the pharmaceuticals company could get?
Jul 1, 2010 by Brian Orelli, PhDIs Dendreon's Provenge in Trouble Before It Starts? Not!CMS questions the coverage of Provenge.
Jun 30, 2010 by Brian Orelli, PhDIs Bristol-Myers Squibb a Buy?If it uses its stash of gold wisely, it is.
Jun 30, 2010 by Brian Orelli, PhDWhich Midsized Biotech Is the Best Buy?Value investing, high-growth style.
Jun 30, 2010 by Brian Orelli, PhDWhen Researchers Attack, Investors LoseWatch out; they're a pesky bunch.
Jun 29, 2010 by Brian Orelli, PhDRedeploying Capital? Investors Hope So.Selling a business unit won't help Abbott Labs diversify.
Jun 29, 2010 by Brian Orelli, PhDDiabetes Drug Development Pops and DropsWhen companies present at a major meeting, there's bound to be both.
Jun 29, 2010 by Brian Orelli, PhDThe Final Obstacle to Your Drug Company MultibaggerThe dreaded FDA advisory committee meeting.
Jun 29, 2010 by Brian Orelli, PhDFoolish Forecast: Monsanto 2.0Views you can use to get clues on tomorrow's news.
Jun 28, 2010 by Brian Orelli, PhDThe Trouble Is They're Facing a BazookaAlcon's minority shareholders are still fighting against Novartis' takeover.
Jun 25, 2010 by Brian Orelli, PhDMark Your Calendars: Obesity Drugs Take Center StageWaiting for the FDA to decide.
Jun 25, 2010 by Brian Orelli, PhDMerck Breathes Life Into an Acquired PipelineThe acquisition is paying off with newly approved drugs.
Jun 25, 2010 by Brian Orelli, PhDThe Joys of Being Large and DiversifiedJohnson & Johnson's plant closure is a rounding error.
Jun 25, 2010 by Brian Orelli, PhDDiversification Times 50,000Gilead Sciences diversifies any way it can.
Jun 24, 2010 by Brian Orelli, PhDSanofi's Secret WeaponDoctors back brand-name Lovenox. Are their motives pure?
Jun 23, 2010 by Brian Orelli, PhDA Novel Drug Technology Worth WatchingRegulus signs up another microRNA partner.
